Collaborations

Complement inhibition license deal signed with Adprotech

Published in Biotech Business Week, May 3rd, 2004

Avant Immunotherapeutics, Inc., (AVAN) announced the signing of a license agreement with Adprotech, Ltd., for non-exclusive rights to use certain components of Avant's intellectual property surrounding complement inhibition.

The license will enable Adprotech to continue further development and commercialization of its APT070 product, which is currently in a clinical trial in rheumatoid arthritis. No rights to either of Avant's complement programs, TP10 and TP20, were transferred under the license. All rights to these two products remain fully owned worldwide by Avant.

Financial details of the agreement with Adprotech were not disclosed, but include...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry